Xuebin Qin Selected Research

Streptococcus intermedius intermedilysin protein

1/2020	Kupffer cells promote T-cell hepatitis by producing CXCL10 and limiting liver sinusoidal endothelial cell permeability.
4/2014	Rapid degradation of the complement regulator, CD59, by a novel inhibitor.
9/2010	The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xuebin Qin Research Topics

Disease

12	Infections 01/2022 - 10/2006
12	Neoplasms (Cancer) 01/2021 - 09/2008
10	Inflammation (Inflammations) 01/2021 - 01/2004
8	Atherosclerosis 01/2021 - 01/2004
6	COVID-19 06/2022 - 01/2020
5	Ischemia 01/2021 - 01/2004
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 06/2017
4	Reperfusion Injury 01/2021 - 01/2004
4	Hemolysis 01/2016 - 01/2008
4	Lymphoma (Lymphomas) 01/2016 - 03/2011
3	Acquired Immunodeficiency Syndrome (AIDS) 01/2017 - 07/2009
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2016 - 09/2008
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2012 - 03/2011
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2012 - 09/2008
3	Hemolytic Anemia 02/2009 - 02/2003
2	Hyperlipidemias (Hyperlipidemia) 01/2021 - 01/2020
2	Metabolic Diseases (Metabolic Disease) 01/2018 - 02/2016
2	HIV Infections (HIV Infection) 01/2018 - 04/2014
2	Vascular Diseases (Vascular Disease) 05/2014 - 01/2004
2	Virus Diseases (Viral Diseases) 04/2014 - 01/2010
2	Liver Diseases (Liver Disease) 12/2011 - 10/2006
2	Thrombosis (Thrombus) 04/2009 - 01/2004
1	Body Weight Changes 01/2022
1	Genetic Predisposition to Disease (Genetic Predisposition) 11/2021
1	Immune System Diseases (Immune Disorders) 01/2021
1	Hemorrhage 01/2021
1	Edema (Dropsy) 01/2021
1	Body Weight (Weight, Body) 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Measles 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Viremia 01/2021
1	Atherosclerotic Plaque (Atheroma) 01/2021
1	Hepatitis 01/2020
1	Neointima 01/2019
1	Hypoxia (Hypoxemia) 01/2018
1	Substance-Related Disorders (Drug Abuse) 06/2017
1	Dyslipidemias (Dyslipidemia) 06/2017
1	Opportunistic Infections (Opportunistic Infection) 06/2017

Drug/Important Bio-Agent (IBA)

21	Complement System Proteins (Complement)IBA 01/2021 - 02/2003
12	Proteins (Proteins, Gene)FDA Link 06/2022 - 02/2002
11	CytokinesIBA 01/2021 - 01/2004
7	Apolipoproteins E (ApoE)IBA 01/2021 - 02/2009
6	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2021 - 02/2009
5	EnzymesIBA 01/2020 - 07/2015
5	Biomarkers (Surrogate Marker)IBA 01/2019 - 11/2011
5	Rituximab (Mabthera)FDA Link 01/2012 - 09/2008
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2017
3	ChemokinesIBA 01/2021 - 01/2020
3	RNA (Ribonucleic Acid)IBA 01/2021 - 07/2012
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 01/2016
3	Streptococcus intermedius intermedilysin proteinIBA 01/2020 - 09/2010
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 09/2010 - 01/2008
2	AntibodiesIBA 06/2022 - 01/2021
2	Interleukin-6 (Interleukin 6)IBA 06/2022 - 01/2021
2	Hematoxylin (Haematoxylon)IBA 01/2022 - 02/2017
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2022 - 02/2017
2	Complement Inactivating AgentsIBA 01/2021 - 05/2014
2	Tryptophan (L-Tryptophan)FDA Link 01/2020 - 01/2019
2	InterleukinsIBA 01/2020 - 01/2016
2	LipopolysaccharidesIBA 01/2016 - 01/2016
2	InflammasomesIBA 01/2016 - 01/2016
2	Monoclonal AntibodiesIBA 04/2014 - 03/2011
2	ofatumumab FDA Link 01/2012 - 11/2011
2	cobra venom factorIBA 12/2011 - 09/2008
1	Antiviral Agents (Antivirals)IBA 06/2022
1	AngiotensinsIBA 01/2022
1	Viral AntigensIBA 01/2022
1	Viral ProteinsIBA 01/2022
1	Interleukin-33IBA 11/2021
1	Volatile Fatty AcidsIBA 01/2021
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2021
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2021
1	Immunoglobulin M (IgM)IBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	CaspasesIBA 01/2021
1	Interleukin-17 (Interleukin 17)IBA 01/2021
1	LipidsIBA 01/2021
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021
1	Angiotensin-Converting Enzyme 2IBA 01/2021
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021
1	NLR ProteinsIBA 01/2021
1	K-18 conjugate (K18)IBA 01/2021
1	Neutralizing AntibodiesIBA 01/2020
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2020
1	Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)IBA 01/2020
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2020
1	Concanavalin AIBA 01/2020
1	Extracellular Matrix ProteinsIBA 01/2020
1	CC ChemokinesIBA 01/2019
1	Interleukin-18 (Interleukin 18)IBA 01/2018
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2018
1	oil red OIBA 02/2017

Therapy/Procedure

9	Therapeutics 01/2021 - 09/2008
4	Liver Transplantation 11/2021 - 07/2011
2	Highly Active Antiretroviral Therapy (HAART) 01/2019 - 07/2009
2	Transplantation 01/2019 - 04/2016
2	Intravenous Injections 01/2017 - 01/2008
1	Organ Transplantation 01/2021
1	Art Therapy 01/2018